EMA Withdrawn: Daquiran (pramipexole dihydrochloride monohydrate) — Dr. Karl Thomae GmbH

View source ↗

Summary

EMA withdrew Daquiran (pramipexole dihydrochloride monohydrate) from the market; Parkinson's disease was the therapeutic area.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Parkinson Disease

Drugs mentioned

• Daquiran (pramipexole dihydrochloride monohydrate)

Snippet

Status: Withdrawn. Therapeutic area: Parkinson Disease. MAH: Dr. Karl Thomae GmbH. Decision date: 02/02/2006